Merck & Co., Inc. Equity Securities, FV-NI, Gain (Loss)
Merck & Co., Inc. (MRK) reported Equity Securities, FV-NI, Gain (Loss) of $242.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-08-07
- Merck & Co., Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2026-06-30 was $242.00M, a 142.00% increase year-over-year.
- Merck & Co., Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was $168.00M, a 86.67% increase year-over-year.
- Merck & Co., Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was -$195.00M.
- Merck & Co., Inc. equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $373.00M.
- Merck & Co., Inc. equity securities, fv-ni, gain (loss) for fiscal 2025 was $368.00M, a 2528.57% increase from fiscal 2024.
- Merck & Co., Inc. equity securities, fv-ni, gain (loss) for fiscal 2024 was $14.00M, a 95.88% decline from fiscal 2023.
- Merck & Co., Inc. equity securities, fv-ni, gain (loss) for fiscal 2023 was $340.00M.
- Merck & Co., Inc. equity securities, fv-ni, gain (loss) for fiscal 2022 was -$1.42B, a 173.14% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $242.00M 10-Q · filed 2026-08-07 | $411.00M 10-Q · filed 2026-08-07 | $215.00M derived: sum of 3 quarters · filed 2026-08-07 | $588.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $168.00M 10-Q · filed 2026-05-04 | -$27.00M derived: sum of 2 quarters · filed 2026-05-04 | $346.00M derived: sum of 3 quarters · filed 2026-05-04 | $446.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$195.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $178.00M derived: sum of 2 quarters · filed 2026-02-24 | $278.00M derived: sum of 3 quarters · filed 2026-08-07 | $368.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | $373.00M 10-Q · filed 2025-11-05 | $473.00M derived: sum of 2 quarters · filed 2026-08-07 | $563.00M 10-Q · filed 2025-11-05 | $408.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $100.00M 10-Q · filed 2026-08-07 | $189.00M 10-Q · filed 2026-08-07 | $35.00M derived: sum of 3 quarters · filed 2026-08-07 | $4.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $90.00M 10-Q · filed 2026-05-04 | -$65.00M derived: sum of 2 quarters · filed 2026-05-04 | -$96.00M derived: sum of 3 quarters · filed 2026-05-04 | -$40.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$155.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$186.00M derived: sum of 2 quarters · filed 2026-02-24 | -$130.00M derived: sum of 3 quarters · filed 2026-02-24 | $14.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$31.00M 10-Q · filed 2025-11-05 | $25.00M derived: sum of 2 quarters · filed 2025-11-05 | $169.00M 10-Q · filed 2025-11-05 | $268.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $56.00M 10-Q · filed 2025-08-05 | $200.00M 10-Q · filed 2025-08-05 | $299.00M derived: sum of 3 quarters · filed 2026-02-24 | $266.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $143.00M 10-Q · filed 2025-05-02 | $243.00M derived: sum of 2 quarters · filed 2026-02-24 | $210.00M derived: sum of 3 quarters · filed 2026-02-24 | $35.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $100.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $67.00M derived: sum of 2 quarters · filed 2026-02-24 | -$108.00M derived: sum of 3 quarters · filed 2026-02-24 | $340.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$33.00M 10-Q · filed 2024-11-06 | -$208.00M derived: sum of 2 quarters · filed 2024-11-06 | $240.00M 10-Q · filed 2024-11-06 | $184.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$175.00M 10-Q · filed 2024-08-05 | $274.00M 10-Q · filed 2024-08-05 | $217.00M derived: sum of 3 quarters · filed 2025-02-25 | -$154.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $450.00M 10-Q · filed 2024-05-03 | $392.00M derived: sum of 2 quarters · filed 2025-02-25 | $21.00M derived: sum of 3 quarters · filed 2025-02-25 | -$263.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$58.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$429.00M derived: sum of 2 quarters · filed 2025-02-25 | -$713.00M derived: sum of 3 quarters · filed 2025-02-25 | -$1.42B 10-K · filed 2025-02-25 |
| 2022-09-30 | -$371.00M 10-Q · filed 2023-11-03 | -$655.00M derived: sum of 2 quarters · filed 2023-11-03 | -$1.36B 10-Q · filed 2023-11-03 | -$958.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$284.00M 10-Q · filed 2023-08-07 | -$991.00M 10-Q · filed 2023-08-07 | -$587.00M derived: sum of 3 quarters · filed 2024-02-26 | $96.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$708.00M 10-Q · filed 2023-05-05 | -$303.00M derived: sum of 2 quarters · filed 2024-02-26 | $380.00M derived: sum of 3 quarters · filed 2024-02-26 | $660.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $405.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.09B derived: sum of 2 quarters · filed 2024-02-26 | $1.37B derived: sum of 3 quarters · filed 2024-02-26 | $1.94B 10-K · filed 2024-02-26 |
| 2021-09-30 | $683.00M 10-Q · filed 2022-11-03 | $963.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.53B 10-Q · filed 2022-11-03 | $1.91B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $280.00M 10-Q · filed 2022-08-05 | $854.00M 10-Q · filed 2022-08-05 | $1.23B derived: sum of 3 quarters · filed 2023-02-24 | $1.59B derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $574.00M 10-Q · filed 2022-05-05 | $948.00M derived: sum of 2 quarters · filed 2023-02-24 | $1.31B derived: sum of 3 quarters · filed 2023-02-24 | $1.86B derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $374.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $734.00M derived: sum of 2 quarters · filed 2023-02-24 | $1.28B derived: sum of 3 quarters · filed 2023-02-24 | $1.34B 10-K · filed 2023-02-24 |
| 2020-09-30 | $360.00M 10-Q · filed 2021-11-05 | $911.00M derived: sum of 2 quarters · filed 2021-11-05 | $964.00M 10-Q · filed 2021-11-05 | $1.08B derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $551.00M 10-Q · filed 2021-08-09 | $603.00M 10-Q · filed 2021-08-09 | $723.00M derived: sum of 3 quarters · filed 2022-02-25 | $739.00M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $52.00M 10-Q · filed 2021-05-05 | $172.00M derived: sum of 2 quarters · filed 2022-02-25 | $188.00M derived: sum of 3 quarters · filed 2022-02-25 | $246.00M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $120.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $136.00M derived: sum of 2 quarters · filed 2022-02-25 | $194.00M derived: sum of 3 quarters · filed 2022-02-25 | $170.00M 10-K · filed 2022-02-25 |
| 2019-09-30 | $16.00M 10-Q · filed 2020-11-05 | $74.00M derived: sum of 2 quarters · filed 2020-11-05 | $50.00M 10-Q · filed 2020-11-05 | -$3.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $58.00M 10-Q · filed 2020-08-05 | $32.00M 10-Q · filed 2020-08-05 | -$19.00M derived: sum of 3 quarters · filed 2021-02-25 | $179.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$25.00M 10-Q · filed 2020-05-06 | -$77.00M derived: sum of 2 quarters · filed 2021-02-25 | $121.00M derived: sum of 3 quarters · filed 2021-02-25 | $274.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$52.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $146.00M derived: sum of 2 quarters · filed 2021-02-25 | $299.00M derived: sum of 3 quarters · filed 2021-02-25 | $324.00M 10-K · filed 2021-02-25 |
| 2018-09-30 | $198.00M 10-Q · filed 2019-11-05 | $351.00M derived: sum of 2 quarters · filed 2019-11-05 | $376.00M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $153.00M 10-Q · filed 2019-08-06 | $178.00M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $25.00M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $352.00M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $43.00M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |